Barinthus Biotherapeutics plc
BRNS
$0.72
-$0.02-2.64%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -75.88M | -69.43M | -65.23M | -61.07M | -57.83M |
| Total Depreciation and Amortization | 3.16M | 3.74M | 3.20M | 2.60M | 2.61M |
| Total Amortization of Deferred Charges | 3.20M | 3.20M | 3.20M | 3.20M | 3.20M |
| Total Other Non-Cash Items | 27.51M | 26.84M | 25.63M | 23.73M | 13.82M |
| Change in Net Operating Assets | 11.36M | -2.48M | 1.18M | 2.60M | -23.43M |
| Cash from Operations | -30.65M | -38.12M | -32.02M | -28.94M | -61.63M |
| Capital Expenditure | -315.00K | -429.00K | -589.00K | -892.00K | -461.00K |
| Sale of Property, Plant, and Equipment | 451.00K | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 136.00K | -429.00K | -589.00K | -892.00K | -461.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 839.00K | 1.30M | 1.66M | 2.16M | 1.44M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 0.00 |
| Cash from Financing | 839.00K | 1.30M | 1.66M | 2.16M | 1.44M |
| Foreign Exchange rate Adjustments | -752.00K | 7.26M | 1.56M | -2.02M | 6.45M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -30.43M | -29.99M | -29.39M | -29.69M | -54.21M |